Letter re: Prophylactic Enoxaparin Dosing Using Anti-Factor Xa Levels in Hepatic Surgery Patients: A Pilot Study

Abstract

Get full access to this article

View all access options for this article.

References

Coster

Shammout

Chaney

, et al. Prophylactic enoxaparin dosing using anti-factor Xa levels in hepatic surgery patients: a pilot study. Am Surg. 2024;90(6):1760-1762. doi:10.1177/00031348241239926

Sikes

Charles

Antigua

Patel

Imboywa

Cherian

. Anti-factor Xa level monitoring for enoxaparin prophylaxis and treatment in high-risk patient groups. HCA Healthc J Med. 2023;4(2):105-109. doi:10.36518/2689-0216.1464

Chanas

Gibson

Langenstroer

, et al. Multicenter study evaluating target attainment of anti-Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients. Pharmacotherapy. 2024;44(3):258-267. doi:10.1002/phar.2904

Flynn

Baldassarra

Hamidi

. Enoxaparin is safe for the treatment of venous thromboembolisms in patients with renal dysfunction: a retrospective cohort study. Thromb Res. 2024;236:127-129. doi:10.1016/j.thromres.2024.02.027

Nemeth

Isherwood

. Safety and effectiveness of reduced dose versus standard dose enoxaparin venous thromboembolism prophylaxis in underweight medically ill patients. Hosp Pharm. 2023;58(2):178-182. doi:10.1177/00185787221123220